Kinnate Biopharma Inc. Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
Received FDA clearance of IND application for brain-penetrant MEK inhibitor, KIN-7136; expect to enter the clinic with Phase 1 trial in the second half of 2023Cash, cash equivalents and investments of...
United States Priyanka Shah Kinnate Biopharma Nima Farzan American Chemical Society American Society Of Clinical Oncology Annual Meeting
Source: marketscreener.com